Factor II (Prothrombin) Mutation: Test & Results

Overview: Understanding the Factor II (Prothrombin) Mutation

One of the most common questions I hear in my haematology clinic is, “Why did I get a blood clot at such a young age?” Often, the answer lies in a genetic predisposition — and the Factor II (Prothrombin) G20210A mutation is among the most prevalent inherited risk factors for venous thromboembolism (VTE). This mutation affects the prothrombin gene, leading to higher-than-normal levels of prothrombin (Factor II) in the blood, which in turn increases the tendency to form clots.

In my practice, patients who discover this mutation often feel a mix of worry and relief — worry about future clotting risks, but relief at finally understanding the cause. Let’s walk through what this test means, who should consider it, and how it influences everyday medical decisions.

What Is a Factor II (Prothrombin) Mutation?

The Factor II mutation is a specific change in the DNA sequence of the prothrombin gene (F2). The most common variant is called G20210A — a guanine-to-adenine substitution at position 20210. This single-letter change boosts prothrombin production by about 30% in carriers, creating a mild but meaningful hypercoagulable state.

It is inherited in an autosomal dominant pattern, meaning only one copy of the mutated gene from either parent increases your risk. About 2–3% of Caucasians carry this mutation, making it the second most common inherited thrombophilia after Factor V Leiden. It is far less common in people of African or Asian ancestry.

How Is the Factor II Mutation Tested?

Testing is a straightforward DNA analysis done on a simple blood sample. The laboratory looks specifically for the G20210A variant in the F2 gene. Results are reported as:

No special preparation or fasting is needed. The test is often ordered alongside Factor V Leiden and sometimes a lupus anticoagulant panel when investigating unexplained clots.

Who Should Be Tested for the Factor II Mutation?

I typically recommend testing for individuals who have had:

• A first venous thromboembolism (deep vein thrombosis or pulmonary embolism) before age 50
• Recurrent VTE without a clear trigger
• Unexpected thrombosis in an unusual site (e.g., cerebral vein, mesenteric vein)
• A first-degree relative with a known Factor II mutation or unexplained VTE

Routine screening of the general population is not recommended, as the absolute risk remains low and many carriers never develop a clot.

Factor II Mutation and Pregnancy

Pregnancy already increases clotting risk about 5-fold. Having a Factor II mutation further elevates that risk — particularly for women who are heterozygous or homozygous. The key concerns include deep vein thrombosis, pulmonary embolism, and, less commonly, placental thrombosis which can contribute to miscarriage, pre-eclampsia, or intrauterine growth restriction.

In my practice, pregnant women with this mutation are often considered for low-molecular-weight heparin (LMWH) prophylaxis during pregnancy and for 6 weeks postpartum, especially if they have a personal or strong family history of clots. Each plan is individualised after a careful risk-benefit discussion.

Does the Factor II Mutation Increase Risk for Arterial Clots?

Unlike some thrombophilias, the Factor II mutation shows a weaker association with arterial thrombosis (heart attack, stroke). The risk appears to be minimal in the absence of other factors like smoking, hypertension, or oral contraceptive use. For young women with the mutation who also use combined hormonal contraception, the relative risk of venous thrombosis is multiplicative — about 15–20 times higher than non-carriers not on the pill. That’s why we often advise alternative contraceptive methods in these patients.

Is There a Treatment for Factor II Mutation?

There is no “cure” for the genetic mutation itself. Management focuses on preventing and treating blood clots. For someone who has already had a VTE, anticoagulation (typically with warfarin, apixaban, rivaroxaban, or LMWH) is standard, often for a longer duration or indefinitely if the clot was unprovoked or recurrent.

For mutation carriers who have never had a clot, the decision to use preventive anticoagulation is nuanced. I rarely recommend lifelong blood thinners for an asymptomatic carrier unless additional risk factors (such as major surgery, prolonged immobilisation, or a strong family history) are present. Instead, we emphasise awareness — knowing the signs of DVT (leg swelling, pain) and PE (sudden chest pain, shortness of breath) — and using temporary prevention during high-risk situations.

Living with a Factor II Mutation: What My Patients Ask

After a positive result, most people want to know what they can and cannot do. The good news: the majority of carriers live clot-free lives. Staying active, maintaining a healthy weight, staying hydrated, and moving your legs during long flights or car rides all help lower the risk. If you smoke, stopping is particularly important.

I always encourage my patients to carry a medical alert card or wear a medical ID bracelet listing their mutation, especially if they are on anticoagulation. This small step can be lifesaving in an emergency.